WOODBRIDGE, ON, Aug. 28, 2013 /CNW/ - Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CNSX: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies
for cardiovascular disease (CVD) and overall health, announced its
second quarter financial results for the three and six months ended
June 30, 2013.
For the three months ended June 30, 2013 the Company reported sales of
$93,189 versus $26,408 over the same period in the previous year. Net
loss for the period is $721,517 or $0.01 per common share as compared
to $874,313 or $0.01 per common share in the previous year.
"I am very pleased to report continued increasing sales of VASCAZEN®," said Mr. Eugene Bortoluzzi, Chief Executive Officer and Chief
Financial Officer. "A growing number of physicians and health care
professionals are realizing the advantages of treating an Omega-3
deficiency by using VASCAZEN® and are impressed by the results they are seeing."
The consolidated financial statements, accompanying notes and the
Management's Discussion and Analysis for the three and six months ended
June 30, 2013, will be accessible on SEDAR www.sedar.com, CNSX www.cnsx.ca under the symbol "PVO" and OTCQX www.otcqx.com under the symbol "PVTTF".
Pivotal also notes the departure of Mr. Giuseppe Simeone, who stepped
down as a director of the Company effective August 27, 2013. Pivotal
wishes to acknowledge and thank Mr. Simeone for his contributions and
guidance since the Company went public and to wish him all the best in
his future endeavours.
Pivotal Highlights for the First Half of 2013:
Sales increased by 27% in the second quarter of 2013;
Successfully completed the VASCAZEN®-REVEAL Trial meeting primary and secondary endpoints, in eight weeks of treatment
with VASCAZEN®patients corrected an Omega-3 deficiency with positive concomitant
effects on their lipid profiles, mainly a 48% reduction of
triglycerides and a positive increase of HDL (good cholesterol) without
negative impact on the LDL-C (bad cholesterol) lipid profile.
Presented results of the VASCAZEN®-REVEAL Trial at the American Heart Association's Arteriosclerosis, Thrombosis and
Vascular Biology (ATVB) 2013 Scientific Sessions;
Dr. Jackowski, Pivotal's founder, Chairman and Chief Scientific Officers
honoured with Queen Elizabeth's Diamond Jubilee Medal for his
contribution to Canadian biotech and the significant improvement in the
quality of life and care for cardiac patients with the development of
the rapid format cardiac blood test;
Exhibited at the American College of Cardiology's 62nd Annual Scientific Session and Expo.
Pivotalʼs Goals for 2013 include:
Advancement of commercialization of Vascazen®;
Expansion of the sales & marketing team;
Initiation of new clinical trials;
Completion of existing clinical trials for Vascazen®and publication of scientific data;
Expansion of intellectual property portfolio;
Investigation of international licensing opportunities;
Expansion of product offerings;
Commercialization of OMAZENTM in Canada;
Presentations to the Investment community to increase awareness;
Presentations and attendance at scientific meetings.
VASCAZEN® is currently available in the U.S. as a prescription only Medical Food
specifically formulated for the dietary management of an Omega-3
deficiency in cardiovascular patients. VASCAZEN® is a >90% pure Omega-3 with a proprietary 6:1 EPA:DHA fatty acid
formulation, protected by a series of both U.S. and foreign patents. VASCAZEN® is the second to market prescription only Omega-3 in the U.S. and is
available by prescription nationwide.
VASCAZEN® has been clinically shown to correct an Omega-3 deficiency within eight
weeks of treatment with positive concomitant effects on the lipid
profiles, mainly a 48% reduction of triglycerides and an increase of
HDL without negative impact on the LDL-C lipid profile. VASCAZEN®'s results were achieved with a dose of 3 grams of EPA and DHA per day
of a prescription grade, high purity Omega-3.
About Pivotal Therapeutics Inc.
Pivotal Therapeutics is a publicly traded (OTCQX: PVTTF) (CNSX: PVO)
specialty pharmaceutical company with a focus on cardiovascular disease
and overall health. Pivotal Therapeutics' lead product VASCAZEN® is a prescription only Medical Food formulated to meet the dietary
Omega-3 deficient needs of patients with cardiovascular disease through
elevating Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA) to
levels associated with reduced risk of cardiovascular complications. OMAZENTM is a pharmaceutical grade Omega-3 providing over 90% pure Omega-3 in
each capsule for the maintenance of good health. OMAZENTM is a patented product available for sale and distribution in Canada.
The information contained in this document is as of August 28, 2013.
This press release contains forward-looking statements. Such
forward-looking statements are subject to a number of risks,
assumptions and uncertainties that could cause Pivotal's actual results
to differ materially from those projected in such forward-looking
statements. These statements can be identified by the use of words such
as "will", "anticipate", "estimate", "expect", "project", "forecast",
"intend", "plan", "believe", "project", "potential", and similar
expressions with any discussion of future operating or financial
performance or events. In particular, factors that could cause actual
results to differ materially from those in forward looking statements
include the following: Pivotal's inability to obtain additional
financing on acceptable terms; growth in costs and expenses; inability
to compete with others who provide comparable products; risk that the
Company's products will not gain widespread market acceptance; risks
relating to the Company's ability to maintain its CSNX listing.
Forward-looking statements speak only as of the date made and are not
guarantees of future performance. The Company undertakes no obligation
to publicly update or revise any forward-looking statements contained
in this document as a result of new information or future events or
developments. CNSX has not reviewed and does not accept responsibility
for the adequacy or accuracy of this information.
SOURCE: Pivotal Therapeutics Inc.